![](/images/graphics-bg.png)
Promoter Polymorphism of RGS2 Gene Is Associated with Change of Blood Pressure in Subjects with Antihypertensive Treatment : The Azelnidipine and Temocapril in Hypertensive Patients with Type 2 Diabetes Study
Joint Authors
Sugimoto, Ken
Shimaoka, Izumi
Morishita, Ryuichi
Rakugi, Hiromi
Ogihara, Toshio
Ohishi, Mitsuru
Fujisawa, Tomomi
Kamide, Kei
Katsuya, Tomohiro
Source
International Journal of Hypertension
Issue
Vol. 2010, Issue 2010 (31 Dec. 2010), pp.1-7, 7 p.
Publisher
Hindawi Publishing Corporation
Publication Date
2010-08-24
Country of Publication
Egypt
No. of Pages
7
Main Subjects
Abstract EN
We performed a prospective study to examine the genetic effect on the response to a calcium (Ca) channel blocker, azelnidipine and an ACE inhibitor, temocapril treatment in patients with hypertension, as a part of the prior clinical trial, the Azelnidipine and Temocapril in Hypertensive Patients with Type 2 Diabetes Study (ATTEST).
Methods and Results.
All subjects who gave informed consent for genetic research were divided into two groups: the subjects treated with azelnidipine or temocapril, for 52 weeks.
We selected 18 susceptible genes for hypertension and determined their genotypes using TaqMan PCR method.
RNA samples were extracted from peripheral blood, and quantitative real time PCR for all genes was performed using TaqMan method.
One of the polymorphisms of the RGS2 gene was extracted as being able to influence the effect of these treatments to reduce BP.
At eight weeks, BP change showed a significant interaction between the A-638G polymorphism of Regulator of G protein signaling-2 (RGS2) gene and treatment with azelnidipine or temocapril.
There was no gene whose expression was associated with BP phenotypes or the polymorphisms of each gene.
Conclusions.
A-638G polymorphism of the RGS-2 gene could be a predictive factor for therapeutic performance of Ca channel blockers.
American Psychological Association (APA)
Sugimoto, Ken& Katsuya, Tomohiro& Kamide, Kei& Fujisawa, Tomomi& Shimaoka, Izumi& Ohishi, Mitsuru…[et al.]. 2010. Promoter Polymorphism of RGS2 Gene Is Associated with Change of Blood Pressure in Subjects with Antihypertensive Treatment : The Azelnidipine and Temocapril in Hypertensive Patients with Type 2 Diabetes Study. International Journal of Hypertension،Vol. 2010, no. 2010, pp.1-7.
https://search.emarefa.net/detail/BIM-453682
Modern Language Association (MLA)
Sugimoto, Ken…[et al.]. Promoter Polymorphism of RGS2 Gene Is Associated with Change of Blood Pressure in Subjects with Antihypertensive Treatment : The Azelnidipine and Temocapril in Hypertensive Patients with Type 2 Diabetes Study. International Journal of Hypertension No. 2010 (2010), pp.1-7.
https://search.emarefa.net/detail/BIM-453682
American Medical Association (AMA)
Sugimoto, Ken& Katsuya, Tomohiro& Kamide, Kei& Fujisawa, Tomomi& Shimaoka, Izumi& Ohishi, Mitsuru…[et al.]. Promoter Polymorphism of RGS2 Gene Is Associated with Change of Blood Pressure in Subjects with Antihypertensive Treatment : The Azelnidipine and Temocapril in Hypertensive Patients with Type 2 Diabetes Study. International Journal of Hypertension. 2010. Vol. 2010, no. 2010, pp.1-7.
https://search.emarefa.net/detail/BIM-453682
Data Type
Journal Articles
Language
English
Notes
Includes bibliographical references
Record ID
BIM-453682